Flossmoor resident and cancer survivor Ann Jackson launched the Center for Food Equity in Medicine at Flossmoor Community ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...
ZME Science on MSN1h
New AI Blood Test with Lasers Finds Breast Cancer in Its Earliest StageEven if a patient is unable to beat the disease, early-stage detection of cancer can play a crucial role in increasing their ...
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially ...
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback